OncLive TV

Neal Shore, MD, FACS, discusses the phase 3 EMBARK study of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

Joseph Mikhael, MD, discusses treatment advancements and ongoing research in multiple myeloma.

Michael Choi, MD, discusses the potential FDA approval of lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia.

Nicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.

Anthony T. Nguyen, MD, PhD, discusses the methodology of trimodal therapy in patients with muscle-invasive bladder cancer.

Efrat Dotan, MD, discusses the use of geriatric function assessments in elderly patients with gastroesophageal cancer.

Tian Zhang, MD, MHS, discusses the implications of subgroup analyses from the KEYNOTE-564 trial in patients with renal cell carcinoma.

Michael Hagensee, MD, PhD, discusses strategies for cervical cancer prevention and ongoing research investigating barriers to cervical cancer treatment.

Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.

Ricardo D. Parrondo, MD, discusses the phase 1b/2 RedirecTT-1 of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Pooja Advani, MBBS, MD, discusses the advantages of using liquid biopsy in metastatic breast cancer.

Abhishek Tripathi, MD, discusses the significance of data from the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.

Paul D. Nathan, MBBS, PhD, FRCP, discusses the clinical significance of updated data on tebentafusp in metastatic uveal melanoma.

Richard Kim, MD, discusses a real-world investigation of long-term responses with regorafenib in metastatic colorectal cancer.

Sarah Sammons, MD, discusses the rationale for examining brain metastases in HER2-positive breast cancer, highlighting the implications of recent data.

Edgardo S. Santos Castillero, MD, FACP, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer.

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX for patients with metastatic pancreatic ductal adenocarcinoma.

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

Tatyana Feldman, MD, discusses the launch of the TRANSCEND CLL 004 trial in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Jeffrey Zonder, MD, discusses notable unmet needs that remain to be addressed in the treatment of patients with relapsed/refractory multiple myeloma.

Matthew Galsky, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

Benjamin Garmezy, MD, discusses in when to choose an IO/TKI regimen for the treatment of patients with ccRCC.

Susan Marie Lang, MD, discusses the incidence of ocular toxicity following treatment with mirvetuximab soravtansine in ovarian cancer.

Pooja Advani, MBBS, MD, discusses key advancements that have occurred for the treatment of patients with triple-negative breast cancer.

Danai Dima, MD, discusses the mechanism of action of teclistamab and why real-world outcomes with the agent were evaluated in a retrospective study.

Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.

Michael R. Bishop, MD, discusses the FELIX study, highlighting the safety of obe-cel in B-cell acute lymphoblastic leukemia.

Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.

Petros Grivas, MD, PhD, discusses 2023 updates regarding the treatment of patients with metastatic/unresectable urothelial carcinoma.

Samuel U. Takvorian, MD, MS, discusses the evolution of regulatory decisions regarding the use of PARP inhibitors for patients with prostate cancer.